Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

AXSM
Axsome Therapeutics, Inc
stock NASDAQ

At Close
Jul 31, 2026 3:59:55 PM EDT
217.68USD-7.240%(-16.99)781,964
209.88Bid   230.66Ask   20.78Spread
Pre-market
Jul 27, 2026 9:28:30 AM EDT
241.01USD+5.976%(+13.59)0
After-hours
Jul 31, 2026 4:00:30 PM EDT
217.99USD+0.142%(+0.31)82,877
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Nov 9, 2021
11:24AM EST  SVB Leerink Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $65   Benzinga
Nov 8, 2021
07:10AM EST  Axsome Therapeutics Q3 EPS $(0.93) Beats $(0.95) Estimate   Benzinga
07:00AM EST  Axsome Therapeutics Reports Third Quarter 2021 Financial Results   GlobeNewswire Inc
05:06AM EST  Earnings Scheduled For November 8, 2021   Benzinga
Oct 20, 2021
07:00AM EDT  Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time   GlobeNewswire Inc
Oct 18, 2021
07:00AM EDT  Axsome Therapeutics Expands Term Loan Facility with Hercules   GlobeNewswire Inc
Sep 16, 2021
07:57AM EDT  Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial Of AXS-12 In Narcolepsy   RTTNews
07:48AM EDT  The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study   Benzinga
07:05AM EDT  Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial Of AXS-12 In Narcolepsy   Benzinga
07:00AM EDT  Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in   GlobeNewswire Inc
Sep 14, 2021
01:14PM EDT  Axsome Therapeutics shares were trading higher after the company announced FDA has accepted for filing the company's New Drug Application for AXS-07 for the acute treatment of migraine.   Benzinga
07:53AM EDT  Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced Tuesday that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for AXS-07 for the acute treatment of migraine. It has set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2022 for the NDA.   RTTNews
07:50AM EDT  The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout   Benzinga
07:03AM EDT  Axsome Therapeutics Announces FDA Acceptance Of New Drug Application For AXS-07 For Acute Treatment Of Migraine   Benzinga
07:00AM EDT  Axsome Therapeutics Announces FDA Acceptance of New Drug   GlobeNewswire Inc
Aug 30, 2021
07:44AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:21AM EDT  HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Lowers Price Target to $180   Benzinga
Aug 23, 2021
06:23AM EDT  FDA Misses PDUFA Deadline For Axsome's MDD Drug, No Additional Data Sought   RTTNews
06:16AM EDT  UPDATE: Axsome Therapeutics Reports 'The FDA did not request additional information from the Company, and the review of the application is ongoing.'   Benzinga
06:03AM EDT  Axsome Therapeutics Announces Its Review Of The New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder Will 'not be completed by the Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2021'   Benzinga
06:00AM EDT  Axsome Therapeutics Provides Update on the New Drug Application   GlobeNewswire Inc
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
07:14AM EDT  3 Beaten Down Stocks that Could be Ready to Bounce   Benzinga
Aug 15, 2021
12:16PM EDT  The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow   Benzinga
11:06AM EDT  The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
08:00PM EDT  AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Axsome Stockholders and Encourages Investors to Contact the Firm   Business Wire
11:00AM EDT  SVB Leerink Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $75   Benzinga
10:38AM EDT  Truist Securities Maintains Buy on Axsome Therapeutics, Lowers Price Target to $160   Benzinga
10:32AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2021   Benzinga
07:57AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
07:00AM EDT  Mizuho Maintains Buy on Axsome Therapeutics, Lowers Price Target to $55   Benzinga
06:30AM EDT  Morgan Stanley Downgrades Axsome Therapeutics to Equal-Weight, Lowers Price Target to $34   Benzinga
Aug 9, 2021
02:35PM EDT  Mid-Afternoon Market Update: Aterian Falls After Q2 Results; Select Interior Concepts Shares Spike Higher   Benzinga
12:22PM EDT  Mid-Day Market Update: Crude Oil Down 2.5%; Golden Nugget Online Gaming Shares Jump   Benzinga
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
10:55AM EDT  Mid-Morning Market Update: Markets Mixed; DISH Network Profit Beats Estimates   Benzinga
10:25AM EDT  Shares of Axsome Therapeutics, Inc. (AXSM) tanked nearly 40% on Monday morning despite the biopharmaceutical company announcing that its depression treatment achieved primary and secondary goals in a mid-stage trial.   RTTNews
07:20AM EDT  Axsome Therapeutics Says On Jul. 30 Received FDA Letter Regarding NDA For AXS-05 Stating FDA Has 'identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time'   Benzinga
07:07AM EDT  Axsome Therapeutics Q2 EPS $(0.86) Beats $(0.97) Estimate   Benzinga
07:05AM EDT  Axsome Therapeutics Reports Second Quarter 2021 Financial Results   GlobeNewswire Inc
07:01AM EDT  Axsome Therapeutics Announces its Phase 2 Trial Met its Primary and Key Secondary Endpoints   Benzinga
07:00AM EDT  AXS-05 significantly delayed the time to relapse of depression compared to placebo (p=0.002, primary endpoint)   GlobeNewswire Inc
04:11AM EDT  Earnings Scheduled For August 9, 2021   Benzinga
Aug 8, 2021
10:11AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 2, 2021
06:10PM EDT  Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates   Benzinga
Jul 15, 2021
08:17PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. (Axsome or the Company) (NASDAQ:AXSM). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
07:01AM EDT  Axsome to host conference call and webcast on Monday, August 9, 2021 at 8:00 AM Eastern Time   GlobeNewswire Inc
Jul 1, 2021
10:12AM EDT  Axsome Therapeutics National Institutes Of Health ClinicalTrials.gov Study Record Detail For Co.'s 'Open-Label Safety Study of AXS-05 in Subjects With Alzheimer's Disease Agitation,' Study Is Recruiting   Benzinga
Jun 15, 2021
09:34AM EDT  Axsome Therapeutics Targets Submission Of US Application For Fibromyalgia Candidate By 2022   Benzinga
07:16AM EDT  Axsome Therapeutics Plans To Submit NDA For Management Of Fibromyalgia In Q4 Of 2022   RTTNews
07:01AM EDT  Axsome Therapeutics Announces Planned NDA Submission For AXS-14 For Management Of Fibromyalgia; Submission Anticipated In Q4   Benzinga
07:00AM EDT  Axsome Therapeutics Announces Planned NDA Submission for AXS-14   GlobeNewswire Inc
Jun 10, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2021   Benzinga
07:28AM EDT  Berenberg Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $112   Benzinga
May 26, 2021
07:58AM EDT  Morgan Stanley Maintains Overweight on Axsome Therapeutics, Raises Price Target to $105   Benzinga
May 10, 2021
10:09AM EDT  Axsome Therapeutics shares were trading higher after the company reported better-than-expected Q1 EPS results.   Benzinga
07:08AM EDT  Axsome Therapeutics Q1 EPS $(0.78) Beats $(0.87) Estimate   Benzinga
07:00AM EDT  Axsome Therapeutics Reports First Quarter 2021 Financial Results   GlobeNewswire Inc
04:09AM EDT  Earnings Scheduled For May 10, 2021   Benzinga
May 7, 2021
07:00AM EDT  Axsome Therapeutics Joins Mental Health America and other Advocacy   GlobeNewswire Inc
Apr 27, 2021
07:00AM EDT  Axsome to host conference call and webcast on Monday, May 10, 2021 at 8:00 AM Eastern Time   GlobeNewswire Inc
06:32AM EDT  HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $225   Benzinga
Apr 26, 2021
07:54AM EDT  Axsome Therapeutics Stock Jumps As FDA Accepts AXS-05 Application In Major Depressive Disorder   Benzinga
06:06AM EDT  Axsome Therapeutics: FDA Accepts NDA Filing For AXS-05 For Major Depressive Disorder   RTTNews
06:02AM EDT  Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder   Benzinga
06:00AM EDT  FDA grants Priority Review and sets PDUFA action goal date of August 22, 2021   GlobeNewswire Inc
Apr 22, 2021
08:09AM EDT  The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs   Benzinga
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 14, 2021
07:51AM EDT  The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead   Benzinga
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
Mar 2, 2021
07:51AM EST  Morgan Stanley Maintains Overweight on Axsome Therapeutics, Raises Price Target to $104   Benzinga
Mar 1, 2021
07:03AM EST  Axsome Therapeutics Q4 EPS $(0.78) Misses $(0.76) Estimate   Benzinga
07:00AM EST  Axsome Therapeutics Reports Fourth Quarter and Full Year 2020   GlobeNewswire Inc
03:51AM EST  Earnings Scheduled For March 1, 2021   Benzinga
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 19, 2021
07:00AM EST  Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will participate in two upcoming investor conferences:   GlobeNewswire Inc
Feb 16, 2021
07:00AM EST  Axsome to host conference call and webcast on Monday, March 1, 2021 at 8:00 AM Eastern Time   GlobeNewswire Inc
Jan 23, 2021
09:14AM EST  The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More   Benzinga
Jan 8, 2021
10:04AM EST  Benzinga's Top Upgrades, Downgrades For January 8, 2021   Benzinga
09:16AM EST  Jefferies Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $129   Benzinga
Dec 31, 2020
07:50AM EST  Axsome Therapeutics Inc. (AXSM) said that it has initiated ACCORD phase 3 trial of AXS-05 in alzheimer's disease agitation. It expects topline results from the trial will be available in the second half of 2022.   RTTNews
07:06AM EST  Axsome Therapeutics Inc. (AXSM) announced positive efficacy and safety results from phase 3 movement long-term trial of AXS-07 in the acute treatment of migraine.   RTTNews
06:42AM EST  Axsome Therapeutics Begins ACCORD Phase 3 Trial Of AXS-05 In Alzheimer's Disease Agitation   RTTNews
06:15AM EST  Axsome Therapeutics Reports Initiation Of ACCORD Phase 3 Trial Of AXS-05 In Alzheimer's Disease Agitation   Benzinga
06:15AM EST  ACCORD is the second pivotal trial of AXS-05 in Alzheimers disease agitation   GlobeNewswire Inc
06:06AM EST  Axsome Therapeutics Announces Positive Results From Phase 3 MOVEMENT Trial Of AXS-07 In Acute Treatment Of Migraine   RTTNews
06:04AM EST  Axsome Therapeutics Reports Results From Phase 3 MOVEMENT Long-Term Trial Of AXS-07 In Acute Treatment Of Migraine: 'rapidly, substantially, and durably relieved migraine pain and associated symptoms in this trial'   Benzinga
06:00AM EST  Axsome Therapeutics Announces Positive Efficacy and Safety Results   GlobeNewswire Inc
Dec 16, 2020
11:25AM EST  Benzinga's Top Upgrades, Downgrades For December 16, 2020   Benzinga
10:29AM EST  Mizuho Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $120   Benzinga
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
06:05AM EST  Axsome Therapeutics Announces Results From COMET-SI Trial Of AXS-05 In Patients With Major Depressive Disorder Who Have Suicidal Ideation   Benzinga
06:03AM EST  Axsome Therapeutics Reports Positive Results From COMET-SI Trial Of AXS-05 In Patients With Major Depressive Disorder   RTTNews
06:00AM EST  68% reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4   GlobeNewswire Inc
Dec 2, 2020
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
06:10AM EST  Axsome Therapeutics Announces Positive Results From Open-label Phase 2 COMET-TRD Trial Of AXS-05   RTTNews
06:03AM EST  Axsome Therapeutics Announces Results From COMET-TRD Trial Of AXS-05 In Patients With Treatment Resistant Depression; Says 'Rapid and substantial improvement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks'   Benzinga
06:00AM EST  Rapid and substantialimprovement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks (MADRS response), and sustained with long-term treatment   GlobeNewswire Inc
Dec 1, 2020
06:13AM EST  Axsome Therapeutics Announces Positive Results From Phase 3 COMET Long-Term Trial And COMET-AU Trial Of AXS-05   RTTNews
06:02AM EST  Axsome Therapeutics Announces Efficacy And Safety Results From Phase 3 COMET Long-Term Trial And COMET-AU Trial Of AXS-05 In Major Depressive Disorder   Benzinga
06:00AM EST  Rapidand substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response), and sustained over 12 months   GlobeNewswire Inc
Nov 9, 2020
07:50AM EST  Morgan Stanley Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $101   Benzinga
Nov 5, 2020
07:08AM EST  Axsome Therapeutics Q3 EPS $(0.61) Misses $(0.57) Estimate   Benzinga
07:00AM EST  COMET Phase 3 long-term safety trial of AXS-05 in MDD, and MOVEMENT Phase 3 long-term safety trial of AXS-07 in migraine completed   GlobeNewswire Inc
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 4, 2020
07:10AM EST  Axsome Therapeutics and Veeva Systems Partner to Build Axsome's Digital-Centric Commercialization Platform   Benzinga
07:03AM EST  Collaboration provides Axsomeaccess to new digital technologies developed by Veeva   GlobeNewswire Inc
Nov 3, 2020
07:00AM EST  Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of   GlobeNewswire Inc
Nov 2, 2020
08:59AM EST  Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23   Benzinga
Oct 28, 2020
07:00AM EDT  Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time   GlobeNewswire Inc
Sep 29, 2020
09:50AM EDT  Benzinga's Top Upgrades, Downgrades For September 29, 2020   Benzinga
07:47AM EDT  B of A Securities Initiates Coverage On Axsome Therapeutics with Underperform Rating, Announces Price Target of $66   Benzinga
07:00AM EDT  Axsome Therapeutics Announces $225 Million Term Loan Facility with   GlobeNewswire Inc
Sep 24, 2020
06:25AM EDT  Axsome Therapeutics: AXS-07 Shows Strong Efficacy In   RTTNews
06:10AM EDT  Axsome: AXS-07 Demonstrated Faster, More Durable Relief Of Migraine Pain As Compared To Rizatriptan   RTTNews
06:04AM EDT  Axsome Therapeutics Reports Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrated 'Significantly Faster Time To Pain Relief As Compared To Rizatriptan And Significantly Less Relapse Of Migraine Pain As Compared To Rizatriptan'   Benzinga
06:00AM EDT  Significantly faster time to pain relief as compared to rizatriptan (p<0.001)   GlobeNewswire Inc
Sep 21, 2020
07:08AM EDT  Axsome Therapeutics Says Development Plan For AXS-12 For Treatment Of Narcolepsy Has Been Expedited   RTTNews
07:02AM EDT  Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Which Will Include 1 Phase 3 Trial   Benzinga
07:00AM EDT  Single Phase 3 trial to be conducted to support an NDA filing of AXS-12 in the treatment of narcolepsy; trial initiation anticipated 1Q 2021   GlobeNewswire Inc
Sep 17, 2020
07:16AM EDT  Axsome Therapeutics Announces Its AXS-07 Phase 3 Migraine Trial Results Was Selected By The American Acadamy Of Neurology Science Committee As Featured Presentation   Benzinga
07:00AM EDT  Data from MOMENTUM Phase 3 trial to be presented at the 2020 AAN Science Highlights Platform   GlobeNewswire Inc
Sep 14, 2020
06:03AM EDT  Axsome Therapeutics Presents New Data From GEMINI Phase 3 Trial With AXS-05   RTTNews
06:02AM EDT  Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder   Benzinga
06:00AM EDT  Rapid, durable, and statistically significant improvement demonstrated in patient-reported depressive symptoms, as measured by the QIDS-SR-16 total score compared to placebo (p=0.001)   GlobeNewswire Inc
Sep 10, 2020
09:31AM EDT  Benzinga's Top Upgrades, Downgrades For September 10, 2020   Benzinga
06:55AM EDT  Morgan Stanley Initiates Coverage On Axsome Therapeutics with Overweight Rating, Announces Price Target of $102   Benzinga
Sep 8, 2020
07:00AM EDT  Axsome Therapeutics to Present at the Morgan Stanley 18th Annual   GlobeNewswire Inc
Sep 3, 2020
07:00AM EDT  Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, will participate in two upcoming investor conferences:   GlobeNewswire Inc
Aug 31, 2020
07:11AM EDT  Axsome Therapeutics Confirms Pivotal Status And Advancement Of AXS-05 For Alzheimer's Disease Agitation   RTTNews
07:03AM EDT  Axsome Therapeutics to Conduct Phase 3 Trial for AXS-05 for Alzheimer's Following FDA Meeting   Benzinga
07:00AM EDT  Previously completed positive, pivotal ADVANCE-1 trial sufficient with single additional Phase 3 efficacy trial for NDA in Alzheimers disease agitation   GlobeNewswire Inc
Aug 28, 2020
07:01AM EDT  Axsome Therapeutics To Present Data From The CONCERT Phase 2 Trial Of AXS-12 in Narcolepsy At The SLEEP 2020 Annual Meeting Aug. 30   Benzinga
Aug 20, 2020
07:11AM EDT  Axsome Therapeutics Completes Pre-NDA Meeting For AXS-07 For Acute Treatment Of Migraine; On Track To Submit NDA In Q4   RTTNews
07:02AM EDT  Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting For AXS-07 For Acute Treatment Of Migraine   Benzinga
07:00AM EDT  Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for   GlobeNewswire Inc
Aug 10, 2020
07:53AM EDT  Axsome Therapeutics Q2 EPS $(0.49) Beats $(0.62) Estimate   Benzinga
07:05AM EDT  Two NDA submissions, for AXS-05 in MDD and for AXS-07 in migraine, on track for 4Q 2020   GlobeNewswire Inc
07:05AM EDT  Axsome Therapeutics Gives an Update on its AXS-05 Depression Clinical Program   Benzinga
07:00AM EDT  Enrollment complete in the COMET Phase 3 long-term safety trial of AXS-05 in MDD; NDA filing on track for 4Q 2020   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Aug 5, 2020
08:04AM EDT  Axsome Therapeutics Receives FDA Breakthrough Therapy Designation For AXS-12 For The Treatment Of Narcolepsy   Benzinga
07:00AM EDT  Axsome Therapeutics Receives FDA Breakthrough Therapy Designation   GlobeNewswire Inc
Jul 31, 2020
12:56PM EDT  Axsome Therapeutics Option Alert: Sep 18 $90 Calls Sweep (27) near the Ask: 432 @ $4.8 vs 1517 OI; Earnings 8/10 Before Open Ref=$72.09   Benzinga
Jul 30, 2020
07:00AM EDT  Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time   GlobeNewswire Inc
Jul 13, 2020
09:57AM EDT  Axsome Therapeutics shares are trading higher after the company had a successful meeting with the FDA regarding its treatment for major depressive disorder and the company said it plans to submit a new drug application in the fourth quarter.   Benzinga
07:09AM EDT  Axsome Completes Successful FDA Pre-NDA Meeting For AXS-05   RTTNews
07:02AM EDT  Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting For AXS-05 For Treatment Of Major Depressive Disorder; NDA Submission On Track For Q4   Benzinga
07:00AM EDT  Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC